AP -- Novavax said Monday its first-quarter loss grew it ramped up research and development spending for flu vaccines.
Operating expenses rose 62 percent to $11.6 million, largely because the company doubled research spending. Novavax is developing vaccines for swine flu and for other flu strains and respiratory diseases. Its products are several years away from reaching the market, and results edged out most expectations on Wall Street.
